Literature DB >> 34629706

Standard Radiation Dosimetry Models: What Interventional Radiologists Need to Know.

Linzi Arndt Webster1, Alexander Villalobos1, Bill S Majdalany1, Zachary L Bercu1, Ripal T Gandhi2, Nima Kokabi1.   

Abstract

Thoughtful and accurate dosimetry is critical to obtain the safest and most efficacious yttrium-90 (Y90) radioembolization of primary and secondary liver cancers. Three dosimetry models are currently used in clinical practice, namely, body surface area model, medical internal radiation dose model, and the partition model. The objective of this review is to briefly outline the history behind Y90 dosimetry and the difference between the aforementioned models. When applying these three models to a single case, the differences between them are further demonstrated. Each dosimetry model in clinical practice has its own benefits and limitations. Therefore, it is incumbent upon practicing interventional radiologists to be aware of these differences to optimize treatment outcomes for their patients. Thieme. All rights reserved.

Entities:  

Keywords:  BSA model; Dosimetry; MIRD model; Partition Model; Radioembolization; Y90; Yttrium-90

Year:  2021        PMID: 34629706      PMCID: PMC8497093          DOI: 10.1055/s-0041-1732323

Source DB:  PubMed          Journal:  Semin Intervent Radiol        ISSN: 0739-9529            Impact factor:   1.780


  47 in total

Review 1.  Imaging of multistep human hepatocarcinogenesis by CT during intra-arterial contrast injection.

Authors:  Osamu Matsui
Journal:  Intervirology       Date:  2004       Impact factor: 1.763

2.  Efficacy and toxicity related to treatment of hepatocellular carcinoma with 90Y-SIR spheres: radiobiologic considerations.

Authors:  Lidia Strigari; Rosa Sciuto; Sandra Rea; Livio Carpanese; Giuseppe Pizzi; Antonella Soriani; Giuseppe Iaccarino; Marcello Benassi; Giuseppe Maria Ettorre; Carlo Ludovico Maini
Journal:  J Nucl Med       Date:  2010-08-18       Impact factor: 10.057

3.  Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma.

Authors:  Jens Ricke; Heinz Josef Klümpen; Holger Amthauer; Irene Bargellini; Peter Bartenstein; Enrico N de Toni; Antonio Gasbarrini; Maciej Pech; Markus Peck-Radosavljevic; Peter Popovič; Olivier Rosmorduc; Eckart Schott; Max Seidensticker; Chris Verslype; Bruno Sangro; Peter Malfertheiner
Journal:  J Hepatol       Date:  2019-08-14       Impact factor: 25.083

Review 4.  Yttrium-90 hepatic radioembolization: clinical review and current techniques in interventional radiology and personalized dosimetry.

Authors:  Aaron K T Tong; Yung Hsiang Kao; Chow Wei Too; Kenneth F W Chin; David C E Ng; Pierce K H Chow
Journal:  Br J Radiol       Date:  2016-03-24       Impact factor: 3.039

5.  Negative phase 3 study of 90Y microspheres versus sorafenib in HCC.

Authors:  Josep M Llovet; Richard S Finn
Journal:  Lancet Oncol       Date:  2018-02       Impact factor: 41.316

Review 6.  Transcatheter intraarterial therapies: rationale and overview.

Authors:  Robert J Lewandowski; Jean-Francois Geschwind; Eleni Liapi; Riad Salem
Journal:  Radiology       Date:  2011-06       Impact factor: 11.105

7.  Partition Model-Based 99mTc-MAA SPECT/CT Predictive Dosimetry Compared with 90Y TOF PET/CT Posttreatment Dosimetry in Radioembolization of Hepatocellular Carcinoma: A Quantitative Agreement Comparison.

Authors:  Silvano Gnesin; Laurent Canetti; Salim Adib; Nicolas Cherbuin; Marina Silva Monteiro; Pierre Bize; Alban Denys; John O Prior; Sebastien Baechler; Ariane Boubaker
Journal:  J Nucl Med       Date:  2016-06-15       Impact factor: 10.057

8.  Radioembolization for hepatic metastases.

Authors:  Milton J Herba; Michael P Thirlwell
Journal:  Semin Oncol       Date:  2002-04       Impact factor: 4.929

9.  Hepatic radioembolization with yttrium-90 containing glass microspheres: preliminary results and clinical follow-up.

Authors:  J C Andrews; S C Walker; R J Ackermann; L A Cotton; W D Ensminger; B Shapiro
Journal:  J Nucl Med       Date:  1994-10       Impact factor: 10.057

Review 10.  Role of hepatic intra-arterial therapies in metastatic neuroendocrine tumours (NET): guidelines from the NET-Liver-Metastases Consensus Conference.

Authors:  Andrew Kennedy; Lourens Bester; Riad Salem; Ricky A Sharma; Rowan W Parks; Philippe Ruszniewski
Journal:  HPB (Oxford)       Date:  2014-09-04       Impact factor: 3.647

View more
  1 in total

1.  Applied Change Management in Interventional Radiology-Implementation of Percutaneous Thermal Ablation as an Additional Therapeutic Method for Small Renal Masses.

Authors:  Friedrich M Lomoschitz; Harald Stummer
Journal:  Diagnostics (Basel)       Date:  2022-05-24
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.